(CTVA) Corteva - Overview
Sector: Basic Materials | Industry: Agricultural Inputs | Exchange: NYSE (USA) | Market Cap: 53.211m USD | Total Return: 13.4% in 12m
Avg Turnover: 283M
EPS Trend: 34.9%
Qual. Beats: 1
Rev. Trend: 27.0%
Qual. Beats: 1
Warnings
Altman Z'' 1.09 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Garp
Corteva, Inc. is a global agricultural technology company operating through two primary segments: Seed and Crop Protection. The Seed segment focuses on developing germplasm and advanced traits to improve crop yields and resistance to environmental stressors, while the Crop Protection segment provides chemical and biological solutions to manage pests, weeds, and soil health.
The company operates in a highly consolidated global agricultural input sector where research and development cycles typically span several years to achieve regulatory approval and commercial scale. Corteva’s business model integrates digital decision-making tools with physical inputs to optimize farm productivity across major geographic markets including North America, Latin America, and Europe.
For a more detailed analysis of these segments, you may wish to explore the data available on ValueRay.
Headquartered in Indianapolis, Indiana, the firm serves the agricultural input industry by supplying herbicides, insecticides, and nitrogen stabilizers alongside its proprietary seed technologies. This dual-segment approach allows the company to capture value throughout the planting and growing cycles of various row crops and specialty markets.
- Seed pricing power and proprietary trait adoption drive high-margin revenue growth
- Expansion of biologicals and crop protection portfolio offsets generic pricing pressure
- Global corn and soybean acreage fluctuations dictate seasonal demand cycles
- Input cost volatility and raw material inflation impact industrial operating margins
- European and North American regulatory shifts influence pesticide and herbicide approval timelines
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.20 > 1.0 |
| NWC/Revenue: 30.92% < 20% (prev 30.33%; Δ 0.59% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.62b > Net Income 1.16b |
| Net Debt (1.21b) to EBITDA (3.41b): 0.36 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (673.6m) vs 12m ago -1.89% < -2% |
| Gross Margin: 46.81% > 18% (prev 0.45%; Δ 4.64k% > 0.5%) |
| Asset Turnover: 42.17% > 50% (prev 39.96%; Δ 2.21% > 0%) |
| Interest Coverage Ratio: 12.27 > 6 (EBITDA TTM 3.41b / Interest Expense TTM 180.0m) |
| A: 0.13 (Total Current Assets 17.4b - Total Current Liabilities 11.9b) / Total Assets 42.7b |
| B: 0.01 (Retained Earnings 436.0m / Total Assets 42.7b) |
| C: 0.05 (EBIT TTM 2.21b / Avg Total Assets 42.4b) |
| D: -0.14 (Book Value of Equity -2.50b / Total Liabilities 18.1b) |
| Altman-Z'' = 1.09 = BB |
| DSRI: 1.03 (Receivables 9.12b/8.29b, Revenue 17.9b/16.8b) |
| GMI: 0.95 (GM 46.81% / 44.63%) |
| AQI: 0.97 (AQ_t 0.50 / AQ_t-1 0.51) |
| SGI: 1.06 (Revenue 17.9b / 16.8b) |
| TATA: -0.03 (NI 1.16b - CFO 2.62b) / TA 42.7b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 78.28 with a total of 6,431,397 shares traded.
Over the past week, the price has changed by -0.96%,
over one month by -1.37%,
over three months by -2.08% and
over the past year by +13.40%.
Corteva has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CTVA.
- StrongBuy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 89.4 | 14.2% |
P/E Trailing = 43.0054
P/E Forward = 22.6757
P/S = 2.9745
P/B = 2.1842
P/EG = 1.3392
Revenue TTM = 17.9b USD
EBIT TTM = 2.21b USD
EBITDA TTM = 3.41b USD
Long Term Debt = 1.68b USD (from longTermDebt, last quarter)
Short Term Debt = 1.67b USD (from shortTermDebt, last quarter)
Debt = 3.36b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.21b USD (calculated: Debt 3.36b - CCE 2.14b)
Enterprise Value = 54.4b USD (53.2b + Debt 3.36b - CCE 2.14b)
Interest Coverage Ratio = 12.27 (Ebit TTM 2.21b / Interest Expense TTM 180.0m)
EV/FCF = 26.60x (Enterprise Value 54.4b / FCF TTM 2.05b)
FCF Yield = 3.76% (FCF TTM 2.05b / Enterprise Value 54.4b)
FCF Margin = 11.44% (FCF TTM 2.05b / Revenue TTM 17.9b)
Net Margin = 6.50% (Net Income TTM 1.16b / Revenue TTM 17.9b)
Gross Margin = 46.81% ((Revenue TTM 17.9b - Cost of Revenue TTM 9.52b) / Revenue TTM)
Gross Margin QoQ = 48.50% (prev 38.29%)
Tobins Q-Ratio = 1.27 (Enterprise Value 54.4b / Total Assets 42.7b)
Interest Expense / Debt = 5.36% (Interest Expense 180.0m / Debt 3.36b)
Taxrate = 15.50% (133.0m / 858.0m)
NOPAT = 1.87b (EBIT 2.21b * (1 - 15.50%))
Current Ratio = 1.47 (Total Current Assets 17.4b / Total Current Liabilities 11.9b)
Debt / Equity = 0.14 (Debt 3.36b / totalStockholderEquity, last quarter 24.4b)
Debt / EBITDA = 0.36 (Net Debt 1.21b / EBITDA 3.41b)
Debt / FCF = 0.59 (Net Debt 1.21b / FCF TTM 2.05b)
Total Stockholder Equity = 24.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.74% (Net Income 1.16b / Total Assets 42.7b)
RoE = 4.67% (Net Income TTM 1.16b / Total Stockholder Equity 24.9b)
RoCE = 8.31% (EBIT 2.21b / Capital Employed (Equity 24.9b + L.T.Debt 1.68b))
RoIC = 5.93% (NOPAT 1.87b / Invested Capital 31.5b)
WACC = 7.89% (E(53.2b)/V(56.6b) * Re(8.10%) + D(3.36b)/V(56.6b) * Rd(5.36%) * (1-Tc(0.16)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -1.94%
[DCF] Terminal Value 75.07% ; FCFF base≈2.07b ; Y1≈2.03b ; Y5≈2.06b
[DCF] Fair Price = 46.24 (EV 32.1b - Net Debt 1.21b = Equity 30.9b / Shares 668.8m; r=8.35% [WACC [floored]]; 5y FCF grow -2.66% → 2.50% )
EPS Correlation: 34.87 | EPS CAGR: 7.67% | SUE: 1.43 | # QB: 1
Revenue Correlation: 26.99 | Revenue CAGR: 0.64% | SUE: 1.34 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.23 | Chg30d=-4.30% | Revisions=-67% | Analysts=16
EPS next Quarter (2026-09-30): EPS=-0.28 | Chg30d=-13.54% | Revisions=-56% | Analysts=16
EPS current Year (2026-12-31): EPS=3.74 | Chg30d=+1.99% | Revisions=+58% | GrowthEPS=+11.9% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=3.22 | Chg30d=+0.86% | Revisions=+0% | GrowthEPS=+20.7% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -67%